Marta Basaldella

Dr. Marta Basaldella

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Riccardo BortolettoRiccardo Bortoletto
Riccardo Bortoletto
MBMarta Basaldella
Marta Basaldella
ACAnna Candolo
Anna Candolo
MGMarco Garzitto
Marco Garzitto
CCCarla Comacchio
Carla Comacchio
Marco ColizziMarco Colizzi
Marco Colizzi
Autism spectrum disorder (ASD) is a complex neurodevelopmental condition characterized by impaired social communication and restricted or repetitive behavior and interests. Psychic distress is common among individuals with ASD, especially in its milder form (level 1), with anxiety and depression being the most common types. Recent research has identified neuroinflammation and gut dysbiosis as potential neurobiological mechanisms underlying ASD. Palmitoylethanolamide (PEA), an endocannabinoid (eCB)-like compound, has shown promise in modulating such mechanisms and may thus have therapeutic implications for ASD. To date, no clinical trial has evaluated the efficacy of PEA in adults with ASD. This 12-week open-label study will assess the feasibility, tolerability, safety, and efficacy of ultramicronized PEA (um-PEA) in treating symptoms of psychic distress, such as anxiety and depression, in adults with level 1 ASD. Secondary research endpoints will include um-PEA’s effects on levels of personal autonomy and neurocognitive and interpersonal function. From a biological point of view, this study will assess um-PEA’s effects on inflammatory markers, the metabolic profile, eCB system modulation, and microbial composition as potential mechanisms of action for its therapeutic effect. In conclusion, this study will investigate a novel approach to the treatment of adults presenting with psychic distress in the context of level 1 ASD. The results may provide valuable insight into the use of um-PEA as a treatment option for ASD adults, addressing a significant unmet clinical need.

20 May 2024 in Early Intervention in Psychiatry
Verified
Journal Article
Open access
MFMaria Ferrara
Maria Ferrara
MBMarta Basaldella
Marta Basaldella
FVFrancesca Vacca
Francesca Vacca
SWScott W. Woods
Scott W. Woods
BWBarbara C. Walsh
Barbara C. Walsh
LGLUIGI GRASSI
LUIGI GRASSI
Aims: The study aims are to present the Italian adaptation of the Abbreviated Clinical Structured Interview for DSM‐5 Attenuated Psychosis Syndrome (Mini‐SIPS) and illustrate its implementation in a clinical setting.Methods: The Mini‐SIPS was developed from the original extended version as a tool designed to identify, within the clinical high risk (CHR) framework, the DSM‐5 Attenuated Psychosis Syndrome (APS) and to be implemented in clinical settings. The Mini‐SIPS was translated in Italian by a Yale‐certified SIPS trainer, then back‐translated in English by a trained psychologist, then approved by the Mini‐SIPS authors. Since September 2021, the adapted Italian version of the Mini‐SIPS has been implemented at the First Episode Psychosis (FEP) Program in Ferrara, Italy.Results: The Italian version of Mini‐SIPS was successfully administered to 15 individuals subsequently referred to the First Episode Psychosis service in Ferrara. Within this sample, the tool has proven to be both an effective and efficient tool for the identification of CHR and FEP, and a valid instrument to help with the differential diagnosis. It also performed as a valuable guide for retrieving information about psychiatric history, to date the onset of APS and/or full‐blown psychosis, to track the progression from CHR to psychosis or to symptoms resolution and to describe patients' pathways to care.Conclusion: The Mini‐SIPS is an efficient and easy‐to‐use interview to identify the early stages of psychosis and established psychosis in clinical contexts. The Italian adaptation of this interview could be effectively implemented in other Italian FEP Programs as a screening and monitoring tool. Formal validation of the instrument is needed to assessed validity and reliability in the diagnosis of the CHR and FEP.

8 January 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MBMarta Basaldella
Marta Basaldella
MRMichele Rossi
Michele Rossi
MGMarco Garzitto
Marco Garzitto
RRRoberta Ruffilli
Roberta Ruffilli
CFCarlo Francescutti
Carlo Francescutti
MARCO BERTELLIMARCO BERTELLI
MARCO BERTELLI
Background/Objectives: Adults with intellectual disability (ID) experience high rates of psychiatric comorbidity but often face diagnostic challenges and treatment barriers, leading to inappropriate psychotropic medication use. This study examined the extent to which specialized psychiatric assessment and improved diagnostic accuracy had an impact on medication management and clinical outcomes in adults with ID and co-occurring psychiatric disorders. Methods: This observational retrospective study analyzed medical records from 25 adults with ID who underwent specialized psychiatric assessment at a community-based service in Italy between January 2023 and January 2024. Psychopathological diagnoses were established according to Diagnostic Manual—Intellectual Disability, Second Edition (DM-ID2) criteria, based on clinical observation and a comprehensive assessment using validated instruments. Clinical outcomes were assessed using a psychometric tool encompassing multiple psychopathological and behavioral dimensions. Data on psychotropic prescriptions and side effects were also collected. Non-parametric analyses were performed, with significance set at α = 0.05. Results: The proportion of patients with a psychiatric diagnosis increased from 32% to 96% after specialized assessment (p < 0.001), with notable rises in depressive (0% to 32%), bipolar (8% to 36%), anxiety (4% to 24%), and impulse control (0% to 16%) disorders. First-generation antipsychotic prescriptions decreased (from 36% to 8%, p = 0.023), while antidepressant use increased (from 12% to 52%, p = 0.004). The mean number of side effects per patient declined from 1.6 to 0.5 (p < 0.001), particularly the elevated prolactin level and psychomotor retardation. Significant improvements were observed in symptom intensity and frequency across multiple domains, including aggression, mood disturbances, and compulsions (p < 0.001). Conclusions: In this single-center retrospective study, specialized psychiatric assessment was associated with improved diagnostic accuracy, medication management, and clinical outcomes in adults with ID. The increase in psychiatric diagnoses likely reflects improved identification, addressing key challenges in precision diagnosis for people with neurodevelopmental disorders. Although the overall number of prescribed medications remained stable, optimization of treatment regimens reduced first-generation antipsychotic use and related adverse effects. These findings indicates that access to specialized assessment and precision diagnosis could improve psychopharmacological interventions and outcomes for this vulnerable population, but larger, multi-center and longer-term studies are needed to confirm these results.

5 December 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MBMarta Basaldella
Marta Basaldella
MRMichele Rossi
Michele Rossi
MGMarco Garzitto
Marco Garzitto
RRRoberta Ruffilli
Roberta Ruffilli
CFCarlo Francescutti
Carlo Francescutti
MARCO BERTELLIMARCO BERTELLI
MARCO BERTELLI
Background/Objectives: Adults with intellectual disability (ID) experience high rates of psychiatric comorbidity but often face diagnostic challenges and treatment barriers, often leading to inappropriate psychotropic medication use. This study examined the extent to which specialised psychiatric assessment and improved diagnostic accuracy had an im-pact on medication management and clinical outcomes in adults with ID and co-occurring psychiatric disorders. Methods: This observational retrospective study ana-lysed medical records from 25 adults with ID who underwent specialised psychiatric as-sessment at a community-based service in Italy between January 2023 and January 2024. Psychopathological diagnoses were established according to Diagnostic Manu-al-Intellectual Disability 2nd version (DM-ID2) criteria, based on clinical observation and a comprehensive assessment using validated instruments. Clinical outcomes were as-sessed using a psychometric tool encompassing multiple psychopathological and behav-ioral dimensions. Data on psychotropic prescriptions and side effects were also collected. Non-parametric analyses were performed, with significance set at α=0.05. Results: The proportion of patients with a psychiatric diagnosis increased from 32% to 96% after spe-cialized assessment (p< 0.001), with notable rises in depressive (0% to 32%), bipolar (8% to 36%), anxiety (4% to 24%), and impulse control disorders (0% to 16%). First-generation an-tipsychotic prescriptions decreased (from 36% to 8%, p=0.023), while antidepressant use increased (from 12% to 52%, p=0.004). The mean number of side effects per patient de-clined from 1.6 to 0.5 (p< 0.001), particularly the elevated prolactin level, and psychomotor retardation. Significant improvements were observed in symptom intensity and frequency across multiple domains, including aggression, mood disturbances, and compulsions (p< 0.001). Conclusions: Specialised psychiatric assessment substantially improved diag-nostic accuracy, medication management, and clinical outcomes in adults with ID. The increase in psychiatric diagnoses reflects improved identification, addressing key chal-lenges in precision diagnosis for people with neurodevelopmental disorders. Evi-dence-based medication optimisation reduced inappropriate antipsychotic use and side effects. These findings support the need for specialised assessment and precision diagnosis to improve psycho-pharmacological interventions and outcomes for this vulnerable population.